Elevated ALT Levels
US$ 28.42
glp-1 cardiovascular outcome trials receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs | Diabetology GLP-1 receptor agonists and cardiovascular
Description
You're held accountable by group members
While analysts expect a limited earnings impact, this move highlights growing trade headwinds for Indian pharma leaders
2018;13(5):e0198024
Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth (BALANCE) model: Request for applications, manufacturer
